Galapagos N.V. (GLPG) P/E Ratio History
UndervaluedTrading at 5.0x vs 5Y avg 140.5x · 21th percentile · Below historical baseline · Data 2013–2026
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, Galapagos N.V. (GLPG) trades at a price-to-earnings ratio of 5.0x, with a stock price of $27.98 and trailing twelve-month earnings per share of $7.42.
The current P/E is 96% below its 5-year average of 140.5x. Over the past five years, GLPG's P/E has ranged from a low of 1.0x to a high of 1038.4x, placing the current valuation at the 21th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, GLPG trades at a 78% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, GLPG trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GLPG DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GLPG Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
GLPG P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 11.0Lowest | - | +68% | |
| $9B | 30.1 | 1.31 | -25% | |
| $14B | 19.5 | 0.38Best | +58% | |
| $23B | 17.9 | - | +4173%Best | |
| $449B | 107.3 | - | -1% | |
| $1.2T | 53.6 | 1.86 | +96% | |
| $139B | 17.9 | - | -4% | |
| $120B | 17.0 | - | +178% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
GLPG Historical P/E Data (2013–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $30.00 | $7.39 | 4.1x | -97% |
| FY2025 Q4 | Dec 31 2025 | $32.70 | $4.84 | 6.8x | -95% |
| FY2024 Q4 | - | $27.50 | $1.06 | 25.9x | -82% |
| FY2024 Q2 | Jun 30 2024 | $24.78 | $1.02 | 24.3x | -83% |
| FY2024 Q1 | Mar 31 2024 | $32.20 | $0.96 | 33.6x | -76% |
| FY2022 Q3 | Sep 30 2022 | $42.64 | $0.09 | 473.8x | +237% |
| FY2020 Q2 | - | $197.29 | $1.74 | 113.4x | -19% |
| FY2020 Q1 | - | $195.92 | $2.65 | 73.9x | -47% |
| FY2019 Q4 | - | $206.83 | $2.50 | 82.7x | -41% |
| FY2019 Q3 | Sep 30 2019 | $152.66 | $4.55 | 33.6x | -76% |
| FY2017 Q1 | Mar 31 2017 | $86.19 | $0.08 | 1038.4x | +639% |
| FY2016 Q4 | Dec 31 2016 | $64.19 | $1.16 | 55.2x | -61% |
| FY2013 Q3 | Sep 30 2013 | $21.13 | $20.64 | 1.0x | -99% |
| FY2013 Q2 | Jun 30 2013 | $19.95 | $20.93 | 1.0x | -99% |
Average P/E for displayed period: 140.5x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GLPG — Frequently Asked Questions
Quick answers to the most common questions about buying GLPG stock.
What is GLPG's P/E ratio?
Galapagos N.V. (GLPG) trailing twelve-month P/E ratio is 5.0x, based on TTM diluted EPS of $7.42. The 5-year average P/E is 140.5x and the historical range spans 1.0x to 1038.4x.
Is GLPG stock overvalued or undervalued?
GLPG trades at 5.0x P/E, below its 5-year average of 140.5x. At the 21th percentile of its historical range (1.0x–1038.4x), the stock is priced at a discount to its own history.
Is GLPG stock expensive?
No, GLPG is not expensive on a historical basis. The current P/E of 5.0x is below the 5-year average of 140.5x and sits at the 21th percentile of its valuation range.
What is GLPG's historical P/E range?
Over the past 5 years, GLPG's P/E ratio has ranged from 1.0x to 1038.4x, with a median of 33.6x and an average of 140.5x. The current P/E of 5.0x places the stock at the 21th percentile of this range. Full historical data spans 2013–2026.
How does GLPG's P/E compare to the S&P 500?
GLPG trades at 5.0x P/E versus the S&P 500 median of 25.1x. The 80% discount to the market suggests lower growth expectations or perceived higher risk.
How does GLPG's valuation compare to Healthcare peers?
Galapagos N.V. P/E of 5.0x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is GLPG's PEG ratio?
GLPG PEG ratio is N/A, based on a P/E of 5.0x and EPS growth of 333.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is GLPG's earnings yield?
GLPG earnings yield is 19.95%, the inverse of its 5.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.